Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial

Spergel, Jonathan M.; Boguniewicz, Mark; Paller, Amy S.; Hebert, Adelaide A.; Gallagher, Paul R.; McCormick, Calogera L.; Parneix-Spake, Anne; Hultsch, T.

doi:10.1111/j.1365-2133.2007.08001.x

Cited by 19 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…107,108 However, one study of pimecrolimus cream added to fluticasone 0.05% cream did not appear to offer any significant advantage in the treatment of AD flares. 109 …”

Section: Topical Calcineurin Inhibitorsmentioning

confidence: 99%

Guidelines of care for the management of atopic dermatitis

Eichenfield

Tom

Berger

et al. 2014

Journal of the American Academy of Dermatology

1,007

510

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of four sections, treatment of AD with non-pharmacological interventions and pharmacological topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence.

show abstract

“…107,108 However, one study of pimecrolimus cream added to fluticasone 0.05% cream did not appear to offer any significant advantage in the treatment of AD flares. 109 …”

Section: Topical Calcineurin Inhibitorsmentioning

confidence: 99%

Guidelines of care for the management of atopic dermatitis

Eichenfield

Tom

Berger

et al. 2014

Journal of the American Academy of Dermatology

1,007

510

View full text Add to dashboard Cite

show abstract

“…In pimecrolimus twice daily/fluticasone propionate daily combinaaddition, in vitro studies have shown that co-application of tion therapy compared with fluticasone propionate daily monobetamethasone valerate foam with tacrolimus or pimecrolimus therapy in EASI scores and investigator or patient assessments in increases the penetration of betamethasone valerate and the 45 patients participating in a 2-week, within-patient study. [119] TCI, [114] which may increase efficacy. [22] Although further prospective, controlled trials are needed to To date, few clinical studies have investigated combination evaluate combination therapies and determine optimal dosages, therapy with TCIs and TCSs in patients with AD.…”

Section: Clinical Utility and Considerationsmentioning

confidence: 96%

Immunology and Treatment of Atopic Dermatitis

Spergel

2008

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory disease hypothesized to be the product of complex interactions among the host's environment, susceptibility genes, skin barrier dysfunction, and immune system dysregulation. The objective of this article is to describe the pathobiology and treatment of AD, with particular focus on the role of immune system dysregulation and therapies designed to target this. Literature review indicates that there are immunologic differences between the lesional and non-lesional skin of atopic individuals, and that the non-lesional skin of atopic individuals presents an immunologic profile distinct from that of the skin of healthy individuals. Thus, immune system dysregulation is postulated to be a key contributing factor to the complex etiology of AD. Immunomodulatory agents such as topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs), which address the underlying immunopathology of AD, are the foundation for the pharmacologic treatment of flares. TCSs and TCIs both target the inflammatory response responsible for an AD flare but via two distinct mechanisms of action. Whereas TCSs have a more widespread impact on the immune system, the action of TCIs is targeted to the calcineurin pathway and inhibition of T-cell activation. Together, TCSs and TCIs represent the backbone of a long-term treatment strategy for AD.

show abstract

“…Later on, Pimecrolimus applied topically on the skin of infants with atopic dermatitis was investigated. All these studies clearly failed to demonstrate any intervention effect on either allergic sensitization or the development of airway disease .…”

Section: Pharmacological Studies For Secondary Preventionmentioning

confidence: 98%